Navigation Links
Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis

Third Clinical Trial Reconfirms Strong Evidence Pycnogenol(R) Lowers Joint Pain, Symptoms; May Now Have Lasting Effect on Joints Following Cessation

of the Extract

HOBOKEN, N.J., Sept. 3 /PRNewswire/ -- According to the Center for Disease Control (CDC), osteoarthritis, the most common type of arthritis, is on the rise. A new study published in the August journal of Phytotherapy Research, reveals Pycnogenol(R), bark extract from the French maritime pine tree, reduced overall knee osteoarthritis (OA) symptoms by 20.9 percent and lowered pain by 40.3 percent. To date, this is the third clinical trial on osteoarthritis treatment with Pycnogenol(R). This study investigated what happens to joint symptoms after treatment with Pycnogenol is terminated and the results show that no relapse occurred after two weeks. Pycnogenol acts as potent anti-inflammatory and the lasting effects found in this study suggest that Pycnogenol may help the joints to recover.

With osteoarthritis cases on the rise, many are seeking non-traditional medication to help ease the pain and reduce the amount of traditional medication taken. The CDC estimates osteoarthritis affects 34 percent of all adults over the age of 65. In 2005, an estimated 26.9 million adults in the U.S. had osteoarthritis, which was up from 21 million in 1990. While there's no known cure for osteoarthritis, treatments such as nonsteroidal anti- inflammatory drugs (NSAIDs) or analgesics can help reduce pain and also maintain joint movement, to help the quality of life for people living with the disease. In more severe cases, cortisone shots and joint replacement surgery are used to treat OA.

"The current study is in accordance with the two previous Pycnogenol(R) studies for osteoarthritis," said Dr. Peter Rohdewald, one of the researchers of the study. "Again the pain is gradually decreasing during the course of three months treatment with Pycnogenol(R). An improvement is found after the first month and a further improvement is seen after two months, where values are significantly different to the placebo group. This study again showed that patients required significantly less analgesic medication while supplementing with Pycnogenol(R), whereas this was not the case with the placebo-treated control group."

The study was held at Slovakia's Comenius University School of Medicine. One hundred patients with stage I or II OA were included in the study and were randomly allocated to either a Pycnogenol(R) or placebo group. Patients were supplemented with 150 mg Pycnogenol(R) or placebo per day over a period of three months. They were allowed to continue taking their NSAID or analgesics prescribed before the study but had to record every pill taken. The established Western Ontario McMaster questionnaire for joint function was employed to rate the pain level, and obtain measures of joint stiffness and to what extent the arthritis affects participation in daily activities. Patients were investigated in two week intervals over the treatment period of three months and a final time two weeks after discontinuation of medication.

The overall score, summarizing pain, stiffness and daily activities, improved statistical significantly by 20.9 percent in the Pycnogenol(R) group. Interestingly, the joint improvement achieved with Pycnogenol persisted after intake of Pycnogenol was discontinued for four weeks. The joint pain decreased by 40.3 percent after completion of the three months supplementation with Pycnogenol and two weeks later the pain was still 36.1 percent lower than at baseline. Furthermore, 38 percent of patients in the Pycnogenol(R) group required less NSAID's or other analgesic medication for joint pain.

"The anti-inflammatory potency of Pycnogenol(R) explains the success in lowering joint pain and stiffness for arthritic joints," said Rohdewald. "After three recent clinical studies on osteoarthritis, Pycnogenol(R) continues to demonstrate its effectiveness for osteoarthritis symptoms making it a viable, natural and safe alternative for individuals. This is the first study that investigated whether a relapse of symptoms occurs after taking Pycnogenol is stopped. The results show a lasting effect after discontinuation which suggest the anti-inflammatory mechanisms of Pycnogenol has allowed the joints to recover."

In another study this year (also published in the journal of Phytotherapy Research), Pycnogenol(R) was shown to reduce osteoarthritis symptoms by 56 percent. Moreover, patients required 58 percent less standard pain medication, which greatly improved the gastrointestinal complications resulting from the pain medication by 63 percent. Last year, a study on osteoarthritis carried out at the University of Arizona Tucson (published in Nutrition Research) discovered that Pycnogenol(R) was effective for improving pain and joint function. After three months in the Pycnogenol(R) group, there was a reduction of 43 percent in pain, 35 percent in stiffness and 52 percent in physical function subscales, respectively. The placebo group showed no significant scores throughout the entire study.

Horphag Research, the exclusive worldwide distributor of Pycnogenol(R) has filed for several patents for Pycnogenol's(R) application for COX-1 and COX-2 inhibition and treatment of osteoarthritis.

About Pycnogenol(R)

Pycnogenol(R) is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol(R) is available in more than 600 dietary supplements, multi- vitamins and health products worldwide. For more information, visit

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol(R) (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol(R) is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. NHS has the exclusive rights to market and sell Pycnogenol(R) in North America and benefits from more than 35 years of scientific research assuring the safety and efficacy of Pycnogenol(R) as a dietary supplement. For more information about Pycnogenol(R) visit our Web site at

SOURCE Natural Health Science Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
2. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
3. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
4. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
5. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
6. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
7. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
8. Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions, According to Animal Study
9. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
10. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
11. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/25/2015)... total global healthcare industry is expected to grow at a ... has the highest projected growth at 12.7%, and ... ), is second with growth projected at 11.5%. ... In 2013-2014, total government funded healthcare was nearly 68%. Federal ... in 2013-2014. In real terms, out of pocket expenditure increased ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
Breaking Medicine News(10 mins):